DRG Market Assessment 보고서

Idiopathic pulmonary fibrosis (IPF), although a rare disease, is one of the most common interstitial lung diseases (ILDs). It is characterized by an irreversible loss of lung function, leading to…

Treatment of heart failure with reduced ejection fraction (HFrEF) is well-established with a wealth of evidence from clinical trials that support the use of all standard-of-care therapies for CHF…

Beta thalassemia is a rare genetic blood disorder characterized by a substantial reduction in or lack of β-globin protein and resulting in chronic anemia, failure to thrive, jaundice, pallor, poor…

IL-17 inhibitors have set a new efficacy standard in moderate to severe psoriasis, putting pressure on the more established TNF-α inhibitors and the IL-12/23 inhibitor Stelara. Although IL-17…

MARKET OUTLOOK The treatment of Crohn’s disease (CD) includes not only conventional therapies, many of which are generically available, but also potent biologics, which are often reserved for…

The development and commercialization of biosimilars require a significant investment in capital, resources, and time. Biosimilar developers must ensure that they are equipped with the necessary…

MARKET OUTLOOK Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) therapy market. Most inpatients are successfully treated empirically with these agents…

Antipsychotics are the cornerstone of schizophrenia treatment, with the crowded atypical and typical antipsychotic drug classes resulting in a complex treatment algorithm. Given the genericization…

MARKET OUTLOOK Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide spectrum of clinical symptoms ranging from…

Drug treatment of glaucoma focuses on reducing/controlling intraocular pressure and preserving visual function. Given the availability of multiple drug classes—i.e., prostaglandin analogues, beta…

MARKET OUTLOOK Treatment for PsA typically begins with a cDMARD, but often progresses to a tsDMARD or bDMARD within two years. TNFi are the mainstay of treatment for recently treated…

Rheumatoid arthritis (RA) treatment typically begins with one or more conventional DMARDs, followed by a first-line biologic, usually a TNF-α inhibitor. Patients refractory to one or more TNF-α…